ArticleMolecular therapy. Nucleic acids2016
Nucleolin-aptamer therapy in retinoblastoma: molecular changes and mass spectrometry-based imaging.
Article in Molecular therapy. Nucleic acids, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies.Heliyon · 2024Review
- Retinoblastoma: A review of the molecular basis of tumor development and its clinical correlation in shaping future targeted treatment strategies.Indian journal of ophthalmology · 2023Review
- RNA-Binding Proteins in Bladder Cancer.Cancers · 2023Review
- Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.International journal of nanomedicine · 2023Review
- Development and characterization of DNA aptamer against Retinoblastoma by Cell-SELEX.Scientific reports · 2022Article
- Pyrylium based derivatization imaging mass spectrometer revealed the localization of L-DOPA.PloS one · 2022Article
- Review: New horizons in retinoblastoma treatment: an updated review article.Molecular vision · 2022Review
- Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma.Cancer management and research · 2021Article
- Targeting HMGA protein inhibits retinoblastoma cell proliferation.RSC advances · 2018Article
- [Research advances in the role of aptamers in the diagnosis and targeted therapy of pediatric cancer].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Review
- The Bioactivity of D-/L-Isonucleoside- and 2'-Deoxyinosine-Incorporated Aptamer AS1411s Including DNA Replication/MicroRNA Expression.Molecular therapy. Nucleic acids · 2017Article
- Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of Nucleolin.Scientific reports · 2017Article
- Updates in ophthalmic pathology.Indian journal of ophthalmology · 2017Review
- Article
- Mass spectrometry in ocular drug research.Mass spectrometry reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma (RB) is an intraocular childhood tumor which, if left untreated, leads to blindness and mortality. Nucleolin (NCL) protein which is differentially expressed on the tumor cell surface, binds ligands and regulates carcinogenesis and angiogenesis. We found that NCL is over expressed in RB tumor tissues and cell lines compared to normal retina. We studied the effect of nucleolin-aptamer (NCL-APT) to reduce proliferation in RB tumor cells. Aptamer treatment on the RB cell lines (Y79 and WERI-Rb1) led to significant inhibition of cell proliferation. Locked nucleic acid (LNA) modified NCL-APT administered subcutaneously (s.c.) near tumor or intraperitoneally (i.p.) in Y79 xenografted nude mice resulted in 26 and 65% of tumor growth inhibition, respectively. Downregulation of inhibitor of apoptosis proteins, tumor miRNA-18a, altered serum cytokines, and serum miRNA-18a levels were observed upon NCL-APT treatment. Desorption electrospray ionization mass spectrometry (DESI MS)-based imaging of cell lines and tumor tissues revealed changes in phosphatidylcholines levels upon treatment. Thus, our study provides proof of concept illustrating NCL-APT-based targeted therapeutic strategy and use of DESI MS-based lipid imaging in monitoring therapeutic responses in RB.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.